Venus Concept, Inc. (VERO) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

18.66 k

Shareholding (Mar 2025)

FII

0.25%

Held by 7 FIIs

DII

89.26%

Held by 1 DIIs

Promoter

9.54%

How big is Venus Concept, Inc.?

22-Jun-2025

As of Jun 18, Venus Concept, Inc. has a market capitalization of 4.52 million and reported net sales of 61.00 million with a net profit loss of 49.55 million over the last four quarters. The company's shareholder's funds are 2.37 million, and total assets are 68.18 million.

What does Venus Concept, Inc. do?

22-Jun-2025

Venus Concept, Inc. develops and manufactures medical aesthetic devices and operates in the Pharmaceuticals & Biotechnology industry as a micro-cap company. As of March 2025, it reported net sales of $14 million and a net loss of $12 million, with a market cap of $4.52 million.

Should I buy, sell or hold Venus Concept, Inc.?

22-Jun-2025

Who are in the management team of Venus Concept, Inc.?

22-Jun-2025

As of March 2022, the management team of Venus Concept, Inc. includes CEO Domenic Serafino, Directors Keith Sullivan, Scott Barry, Garheng Kong, Louise Lacchin, and Fritz LaPorte.

Is Venus Concept, Inc. technically bullish or bearish?

20-Sep-2025

As of August 27, 2025, Venus Concept, Inc. is in a mildly bearish trend, indicated by bearish daily moving averages and monthly Bollinger Bands, while significantly underperforming the S&P 500 with a year-to-date return of -43.50%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate 5.04% of over the last 5 years
Low ability to service debt as the company has a high Debt to EBITDA ratio of -1.00 times

Flat results in Jun 25

Risky - Negative EBITDA

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 4 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

13.17

Return on Equity

-1,636.18%

Price to Book

1.80

Revenue and Profits:

Net Sales:

16 Million

(Quarterly Results - Jun 2025)

Net Profit:

-12 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-11.42%

6 Months

-18.49%

1 Year

-44.36%

2 Years

-87.84%

3 Years

626.59%

4 Years

-99.03%

5 Years

-99.51%

Venus Concept, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Venus Concept, Inc. technically bullish or bearish?

As of 27 August 2025, the technical trend for Venus Concept, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by bearish signals from the daily moving averages and monthly Bollinger Bands, while the weekly and monthly MACD and KST indicators show mild bullishness. The Dow Theory indicates a mildly bearish trend on the monthly timeframe. In terms of performance, the stock has significantly underperformed against the S&P 500, with a year-to-date return of -43.50% compared to the S&P 500's 12.22%, and a one-year return of -57.67% versus 17.14% for the index....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-2.05%

EBIT Growth (5y)

5.04%

EBIT to Interest (avg)

-4.58

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

14.84

Sales to Capital Employed (avg)

1.36

Tax Ratio

0.62%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

19.14%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.00

EV to EBIT

-1.32

EV to EBITDA

-1.52

EV to Capital Employed

1.06

EV to Sales

0.62

PEG Ratio

Dividend Yield

ROCE (Latest)

-80.79%

ROE (Latest)

-1641.51%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 3 Schemes (0.94%)

Foreign Institutions

Held by 7 Foreign Institutions (0.25%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 15.44% vs -13.92% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 5.65% vs -55.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15.70",
          "val2": "13.60",
          "chgp": "15.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.10",
          "val2": "-8.60",
          "chgp": "5.81%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "1.40",
          "chgp": "-14.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.80",
          "val2": "-1.20",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.70",
          "val2": "-12.40",
          "chgp": "5.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-576.20%",
          "val2": "-698.40%",
          "chgp": "12.22%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -15.18% vs -23.22% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -27.03% vs 15.14% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "64.80",
          "val2": "76.40",
          "chgp": "-15.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-23.30",
          "val2": "-24.20",
          "chgp": "3.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.70",
          "val2": "6.90",
          "chgp": "11.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-10.60",
          "val2": "-2.00",
          "chgp": "-430.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-47.00",
          "val2": "-37.00",
          "chgp": "-27.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-419.30%",
          "val2": "-370.80%",
          "chgp": "-4.85%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

15.70

13.60

15.44%

Operating Profit (PBDIT) excl Other Income

-8.10

-8.60

5.81%

Interest

1.20

1.40

-14.29%

Exceptional Items

-1.80

-1.20

-50.00%

Consolidate Net Profit

-11.70

-12.40

5.65%

Operating Profit Margin (Excl OI)

-576.20%

-698.40%

12.22%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 15.44% vs -13.92% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 5.65% vs -55.00% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

64.80

76.40

-15.18%

Operating Profit (PBDIT) excl Other Income

-23.30

-24.20

3.72%

Interest

7.70

6.90

11.59%

Exceptional Items

-10.60

-2.00

-430.00%

Consolidate Net Profit

-47.00

-37.00

-27.03%

Operating Profit Margin (Excl OI)

-419.30%

-370.80%

-4.85%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -15.18% vs -23.22% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -27.03% vs 15.14% in Dec 2023

All Annual Results

Company CV

About Venus Concept, Inc.

Venus Concept, Inc.

Pharmaceuticals & Biotechnology

Venus Concep, Inc., formerly Restoration Robotics, Inc., develops and manufactures devices for the medical aesthetic market. The Company offers a range of products and services under various brands, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Freeze Plus, Venus Heal, Venus Skin and Venus Bliss. It offers a product portfolio of minimally invasive and non-invasive medical aesthetic technologies in over 60 countries and 29 direct markets. Its hair restoration division includes NeoGraft, an automated hair restoration system that facilitates the harvesting of follicles during a follicular unit extraction (FUE) process. Venus Viva includes NanoFractional Radio Frequency (RF) and SmartScan technology. It offers aesthetic products for the treatment of face, neck and body. Venus Fiore is designed with three applicators to address internal vaginal health restoration, labia skin tightening and mons pubis reduction.

Company Coordinates

Company Details

235 Yorkland Blvd Suite 900 , TORONTO ON : M2J 4Y8

Tel: 1 408 8836888

http://www.restorationrobotics.com/

Registrar Details

Venus Concept, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Venus Concept, Inc.?

Watch in Real-Time

What does Venus Concept, Inc. do?

Should I buy, sell or hold Venus Concept, Inc.?

Who are in the management team of Venus Concept, Inc.?

Is Venus Concept, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Flat results in Jun 25

Risky - Negative EBITDA

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Venus Concept, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Venus Concept, Inc.

Company Coordinates